Investors & Media

Transformative science, targeted medicines

We are working to advanceĀ a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC Filings

SEC Filings

Filing date Form Description View
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
CT ORDER

CT ORDER

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

Pagination